|Positive WB detected in||A549 cells, mouse brain tissue, human placenta tissue|
|Positive IP detected in||mouse brain tissue|
|Positive IHC detected in||human brain tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||HeLa cells|
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:2000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Immunofluorescence (IF)||IF : 1:20-1:200|
|Sample-dependent, check data in validation data gallery|
The immunogen of 20995-1-AP is TMEM106B Fusion Protein expressed in E. coli.
|Tested Reactivity||human, mouse|
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||TMEM106B fusion protein Ag14264|
|Full Name||transmembrane protein 106B|
|Calculated molecular weight||31 kDa|
|Observed molecular weight||31-35 kDa, 40-55 kDa|
|GenBank accession number||BC033901|
|Gene ID (NCBI)||54664|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
TMEM106B is a genetic risk factor for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). Amyotrophic lateral sclerosis (ALS), like FTLD-TDP, is characterized by pathological TDP-43 inclusions. TMEM106B expression in the brain may be linked to mechanisms of disease in FTLD-TDP and risk alleles confer genetic susceptibility by increasing gene expression. TMEM106B can be showed as 31-55 kDa and 70-90 kDa (Glycosylated or Dimer) form in western blot test. (PMID: 27543298, 22895706, PMID: 23136129).
|Product Specific Protocols|
|WB protocol for TMEM106B antibody 20995-1-AP||Download protocol|
|IHC protocol for TMEM106B antibody 20995-1-AP||Download protocol|
|IF protocol for TMEM106B antibody 20995-1-AP||Download protocol|
|IP protocol for TMEM106B antibody 20995-1-AP||Download protocol|
|Click here to view our Standard Protocols|
TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III.
Alzheimers Res Ther
TMEM106B expression is reduced in Alzheimer's disease brains.
TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways.